Georgia Medicare Cancer Screenings: Coverage and Costs (2026)

This guide to Georgia Medicare cancer screenings explains the five cancers Medicare covers, who is eligible, what costs to expect, and how to access screening across Georgia's major cancer centers. Cancer is one of the leading causes of death among older Americans, and the majority of new diagnoses occur in adults age 65 and older. Five cancers (lung, colorectal, breast, prostate, and cervical) have established screening tests that either detect cancer earlier, when treatment is more effective, or detect precancerous lesions where removal prevents cancer altogether.

Medicare covers every major cancer screening modality. Under ACA Section 4104 (the Affordable Care Act provision that waived Medicare cost-sharing for preventive services), Medicare beneficiaries pay $0 in deductibles, coinsurance, or copayments for screening services that the United States Preventive Services Task Force (USPSTF) has graded A or B. That covers screening mammography, screening Pap and HPV testing, screening colonoscopy and fecal testing, and low-dose CT scanning for lung cancer. Screening prostate-specific antigen (PSA) testing is also $0 to the beneficiary, even though its USPSTF grade is C/D, because Section 1861(s)(2)(P) preserved zero cost-sharing through statutory design.

This guide explains the federal coverage framework for each cancer screening, the National Coverage Determination (NCD) that governs it, the Healthcare Common Procedure Coding System (HCPCS) codes your provider uses to bill Medicare, the frequencies and age ranges, common errors that cause beneficiaries to miss screenings or unexpectedly receive bills, and how Georgia beneficiaries access screening through Emory Winship Cancer Institute, Piedmont Cancer Institute, Augusta University Georgia Cancer Center, Wellstar Cancer Network, Northside Hospital Cancer Institute, Atrium Health Navicent Cancer Center, Memorial Health Mercer Cancer Center, Phoebe Cancer Center, the Georgia Breast and Cervical Cancer Program (BCCP) administered by the Georgia Department of Public Health, and Georgia CORE's statewide cancer coordination work.

Brevy is an eldercare company helping families navigate Medicare, Medicaid, and senior-care decisions. This guide is education, not medical advice. For personalized cancer screening recommendations, consult your primary care physician. For coverage questions, call 1-800-MEDICARE.

By Brevy Care Team · Last verified May 21, 2026

Cancer in Medicare-aged Americans is one of the leading age-associated disease burdens. The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute reports that the majority of new cancer diagnoses and cancer deaths occur in adults age 65 and older. The reasons are biological (cumulative DNA damage, declining immune surveillance) and demographic (longer life expectancy means more time at risk). The four cancers that account for a large share of all cancer mortality are amenable to screening:

Lung cancer is the leading cause of cancer death in America. Low-dose CT screening can reduce lung cancer mortality in eligible smokers, making it the only mortality-proven lung cancer screening test.

Colorectal cancer is among the leading causes of cancer death (combining men and women). Screening reduces colorectal cancer mortality through both early detection and precancerous polyp removal (the only cancer screening that prevents cancer rather than merely detecting it earlier).

Breast cancer is the most commonly diagnosed cancer in American women. Screening mammography reduces breast cancer mortality in women age 50 and over.

Prostate cancer is the most common cancer in American men (excluding skin cancer). PSA screening reduces prostate cancer mortality modestly but with substantial harms from overdiagnosis and overtreatment (the source of USPSTF Grade C recommendation for shared decision-making in ages 55-69).

Cervical cancer has been dramatically reduced by screening, with the great majority of new cases occurring in women who were unscreened or inadequately screened. For Medicare-aged women with adequate prior screening, ongoing screening yield is low, but Medicare maintains coverage.

For Georgia, the cancer burden tends to be heavier than the national average. Rural Georgia counties have higher cancer mortality than urban counties. Black Georgians experience higher overall cancer mortality than White Georgians, with particular disparities in prostate cancer and triple-negative breast cancer outcomes.

Screening uptake in Georgia trails national averages across colorectal, mammography, cervical, and lung cancer screenings, with lung cancer screening especially underutilized among eligible Georgians. For state-level rates, consult the current CDC BRFSS state data and Georgia Department of Public Health cancer reports.

Section 1861(s)(2)(R) and NCD 210.3: Colorectal cancer screening

Colorectal cancer is among the leading causes of cancer death in the United States (combining men and women). It is also one of the most preventable common cancers, because screening identifies and removes adenomatous polyps before they progress to invasive cancer. Medicare covers colorectal cancer screening under Section 1861(s)(2)(R) of the Social Security Act, added by the Balanced Budget Act of 1997. The covered modalities and frequencies are detailed in National Coverage Determination 210.3 and the CMS Internet-Only Manual claims-processing chapter for preventive services.

Age threshold

The minimum age for Medicare-covered colorectal cancer screening was reduced from age 50 to age 45 in a recent Medicare Physician Fee Schedule Final Rule, conforming to the USPSTF recommendation update that lowered the threshold (USPSTF currently grades the 45-49 band B and the 50-75 band A). There is no upper age limit in Medicare coverage, although USPSTF recommends individualized decision-making for older adults and against screening at advanced ages.

Covered modalities

Fecal occult blood test (FOBT): HCPCS G0107 (guaiac) or G0328 (fecal immunochemical test, FIT). Annual. Performed at home, mailed to lab. No bowel prep, no sedation, no dietary restrictions for FIT.

Multitarget stool DNA test: HCPCS G0464. The brand name is Cologuard. Covered every 3 years for asymptomatic average-risk beneficiaries ages 45-85. Combines FIT with DNA biomarker testing for higher sensitivity than FIT alone but with more false positives and lower specificity.

Flexible sigmoidoscopy: HCPCS G0104. Every 4 years (or every 10 years following a screening colonoscopy). Examines the rectum and lower portion of the colon. Misses right-sided lesions.

Screening colonoscopy: HCPCS G0105 for high-risk individuals (covered every 24 months) and HCPCS G0121 for average-risk individuals (covered every 10 years, or every 48 months following a screening flexible sigmoidoscopy). Examines the entire colon. The most sensitive option and the only modality that both detects and prevents cancer (polyps can be removed during the same procedure). Carries a small risk of bowel perforation.

High-risk is defined as: family history of colorectal cancer or adenomatous polyps in a first-degree relative; personal history of adenomatous polyps; personal history of inflammatory bowel disease (Crohn's, ulcerative colitis); family history of hereditary syndromes (Lynch, FAP).

Barium enema (rare): HCPCS G0106 as alternative to flexible sigmoidoscopy (every 4 years) or G0120 as alternative to colonoscopy (every 24 months high-risk, every 48 months average-risk). Largely obsolete; included in NCD for completeness.

Cost-sharing

The screening procedure itself is $0 cost-sharing under ACA Section 4104. Critical gotchas:

Follow-up colonoscopy after positive non-invasive test: Historically, if a beneficiary had a positive Cologuard or FIT, the follow-up colonoscopy was billed as diagnostic rather than screening, triggering Part B deductible and 20 percent coinsurance. The Consolidated Appropriations Act of 2021 fixed this. Follow-up colonoscopy after a positive non-invasive test is now billed as part of the screening benefit at $0 cost-sharing.

Polyp removal during screening colonoscopy: Historically, when a polyp was found and removed during screening colonoscopy, the procedure converted to therapeutic and the beneficiary was charged coinsurance. CAA 2021 Section 122 phases this out, with coinsurance scheduled to reach $0 over a multi-year transition. Confirm the current phase-in percentage with your provider or the CMS preventive-services schedule before scheduling.

Anesthesia services during screening colonoscopy: Anesthesia for screening colonoscopy is $0 cost-sharing.

Worked example 1: Roberta, age 67, Atlanta

Roberta, age 67, lives in Atlanta and has Original Medicare (Part A + Part B + a Medigap Plan G). At her Annual Wellness Visit at Emory Decatur Hospital, her primary care physician notes she has never had a screening colonoscopy. Roberta has no family history of colorectal cancer and is therefore average-risk. The PCP offers her Cologuard, screening colonoscopy, or annual FIT and explains the trade-offs. Roberta chooses Cologuard because she prefers to avoid bowel prep and sedation.

The PCP orders G0464 (Cologuard). Medicare pays the lab. Roberta pays $0.

Two weeks later, the result returns positive (presence of DNA markers suggestive of colorectal neoplasia). Roberta now needs a follow-up colonoscopy. Because she had her Cologuard performed in 2026, under the CAA 2021 fix, the follow-up colonoscopy is billed under the screening benefit (G0105 for high-risk individual because positive Cologuard elevates her to high-risk).

She has the colonoscopy at Emory University Hospital. A polyp is found and removed. Pre-CAA 2021, this would have converted to therapeutic billing. Under the current phase-in, she owes coinsurance on the polypectomy portion ($0 on the colonoscopy facility/professional fee). Her Medigap Plan G covers the coinsurance. Roberta's out-of-pocket cost is $0.

Section 1861(s)(13) and NCD 220.4: Screening mammography

Breast cancer is the most commonly diagnosed cancer in American women (excluding non-melanoma skin cancer) and among the leading causes of cancer death in women. Screening mammography reduces breast cancer mortality in women age 50-74 across multiple meta-analyses including Cochrane.

Statutory and regulatory framework

Section 1861(s)(13) of the Social Security Act establishes screening mammography as a Medicare-covered preventive service. The Mammography Quality Standards Act of 1992 requires that all mammography facilities be FDA-certified to ensure quality and consistency. Medicare began covering screening mammography in the early 1990s; coverage was later expanded to annual screening for women age 40 and over.

Frequencies and HCPCS codes

Baseline mammogram: HCPCS 77067 once between ages 35-39 (one in lifetime).

Annual screening mammography: HCPCS 77067 (bilateral) annually for women age 40 and over. No upper age limit. Medicare exceeds the USPSTF 2024 recommendation of biennial screening 40-74.

Screening digital breast tomosynthesis (3D): HCPCS 77063 add-on code. Covered as adjunct to 2D mammography when ordered.

Diagnostic mammography: HCPCS 77065 (unilateral) and 77066 (bilateral). Used when there is a clinical sign or symptom (lump, pain, nipple discharge, prior abnormal screening). Diagnostic mammography is NOT $0 cost-sharing; Part B deductible and 20 percent coinsurance apply.

Cost-sharing

Screening mammography is $0 cost-sharing under ACA Section 4104. No deductible, no coinsurance, no copayment for the screening itself. The "screening to diagnostic conversion" gotcha applies: if the screening identifies an abnormality requiring biopsy, the biopsy is a separate diagnostic service with 20 percent coinsurance.

Facility requirements

The performing facility must be FDA-certified under MQSA. Most hospital outpatient departments, dedicated breast centers, and accredited mobile units are certified. Beneficiaries can verify certification at fda.gov/radiation-emitting-products/mammography-quality-standards-act-and-program.

Worked example 2: Patricia, age 72, Macon

Patricia, age 72, lives in Macon and has Original Medicare with a Medigap Plan G. She has had annual screening mammography for 25 years. Her PCP at Atrium Health Navicent orders her annual screening mammogram, performed at the Navicent Cancer Center.

HCPCS 77067 is billed to Medicare. Patricia pays $0.

The radiologist reads the films as BI-RADS 4 (suspicious for malignancy) and recommends diagnostic mammography with ultrasound and core biopsy. This converts to diagnostic billing. The diagnostic mammogram (77066) and ultrasound (76641) are charged with 20 percent coinsurance applied to Medicare-allowed amounts. The core biopsy (19083) likewise incurs coinsurance. Patricia's Medigap Plan G covers the entire 20 percent coinsurance. Out-of-pocket: $0.

The biopsy returns ductal carcinoma in situ (DCIS), stage 0. Patricia proceeds to lumpectomy with sentinel lymph node biopsy at Atrium Health Navicent, followed by radiation therapy. Patricia's adherence to annual mammography for 25 years detected the cancer at stage 0, when long-term survival is excellent, rather than at clinical stage (palpable, typically stage II+).

Section 1861(s)(14) and NCD 210.2: Cervical cancer screening (Pap and pelvic exam)

Cervical cancer kills several thousand American women each year, the vast majority of whom were unscreened or inadequately screened. The disease is almost entirely caused by persistent infection with high-risk human papillomavirus (HPV) types. The Pap smear, introduced clinically in the late 1940s, has been one of the most successful cancer screening tests in history; combined with HPV testing, cervical cancer mortality has fallen dramatically since the 1950s.

Statutory and regulatory framework

Section 1861(s)(14) of the Social Security Act establishes Medicare coverage for screening pelvic exam and Pap test. NCD 210.2 details specifics. The CMS Internet-Only Manual claims-processing chapter for preventive services governs administration.

Frequencies and HCPCS codes

Screening pelvic and clinical breast exam: HCPCS G0101. Every 24 months average-risk; every 12 months high-risk.

Screening Pap collection (obtaining the specimen): HCPCS Q0091. Every 24 months average-risk; every 12 months high-risk.

Pap smear screening technical: HCPCS P3000.

Pap smear screening professional: HCPCS P3001.

HPV co-testing: HCPCS G0476 (HPV high-risk testing as screening). Every 5 years for women ages 30-65 with negative co-test results.

High-risk for cervical cancer is defined per NCD 210.2 as: early onset of sexual activity (under 16); five or more lifetime sexual partners; history of sexually transmitted disease including HPV infection; less than three negative Pap smears within previous 7 years; daughters of women who took DES (diethylstilbestrol) during pregnancy.

Cost-sharing

Screening Pap and pelvic exam are $0 cost-sharing under ACA Section 4104.

Cessation age

USPSTF recommends ceasing cervical cancer screening at age 65 in women with adequate prior negative screening history (three negative cytology tests or two negative co-tests in past 10 years, most recent within 5 years). Medicare does not enforce an upper age limit on Pap coverage, and practitioners may continue screening based on individual assessment of prior screening adequacy, sexual history, and risk factors.

Worked example 3: Mary, age 65, Augusta

Mary, age 65, lives in Augusta and was newly diagnosed with cervical dysplasia 8 years ago (resolved with conization). Because of her history, she is high-risk and her Augusta University Health gynecologist orders annual Pap with HPV co-test.

She receives G0101 (pelvic/clinical breast exam), Q0091 (obtaining Pap), P3001 (Pap professional), and G0476 (HPV co-test). All are $0 cost-sharing. Medicare pays AU Health for the visit and lab fees. Mary pays $0.

Her HPV co-test is positive for HPV-16 (a high-risk strain). The gynecologist orders colposcopy with biopsy, which converts to diagnostic billing. The colposcopy (57452) and biopsy (57454) are charged with 20 percent coinsurance applied. Mary has a Medicare Advantage Plan with a moderate maximum out-of-pocket; her coinsurance on these services is modest. The biopsy is benign cervicitis with low-grade dysplasia, not high-grade. Mary continues annual surveillance per her gynecologist.

Section 1861(s)(2)(P) and NCD 210.1: Prostate cancer screening

Prostate cancer is the most common cancer in American men (excluding skin cancer) and the second leading cause of cancer death in men. PSA screening is the most controversial of the major cancer screening tests because it identifies many indolent cancers (overdiagnosis) that, if treated, cause more harm than benefit. The USPSTF currently recommends individualized shared decision-making for men ages 55-69 (Grade C) and recommends against routine screening at age 70 and over (Grade D).

Statutory framework

Section 1861(s)(2)(P) of the Social Security Act, added by the Balanced Budget Act of 1997, established Medicare coverage for prostate cancer screening. NCD 210.1 details coverage; the CMS Internet-Only Manual claims-processing chapter for preventive services governs administration.

Frequencies and HCPCS codes

Digital rectal exam (DRE): HCPCS G0102. Annual for men age 50 and over.

PSA blood test: HCPCS G0103. Annual for men age 50 and over.

There is no upper age limit in Medicare coverage. Coverage begins at the day after the beneficiary's 50th birthday.

Cost-sharing

The DRE (G0102) historically had coinsurance applied because it is a physical exam (paid under the physician fee schedule). Under the Medicare Improvements for Patients and Providers Act (MIPPA), G0102 became $0 cost-sharing. The PSA test (G0103) is also $0 cost-sharing. Medicare maintains $0 cost-sharing on prostate screening through statute rather than through ACA Section 4104 (which only covers USPSTF Grade A/B services, and prostate screening is currently Grade C/D).

Shared decision-making

Although Medicare maintains screening coverage, USPSTF Grade C for ages 55-69 carries a meaningful clinical message: the decision should be individualized based on personal risk (family history, race, prior PSA trajectory), values regarding overdiagnosis and treatment harms, and life expectancy. Beneficiaries with serious comorbid disease and limited life expectancy benefit less from screening because indolent prostate cancers are unlikely to cause death within remaining life.

Worked example 4: James, age 70, Savannah

James, age 70, lives in Savannah, is African American (elevated prostate cancer risk), and has a brother with prostate cancer (further elevated risk). He has Original Medicare. His PCP at Memorial Health Mercer Cancer Center orders annual PSA and DRE.

HCPCS G0102 and G0103 are billed. Medicare pays the provider; James pays $0.

His PSA returns elevated above the typical reference threshold used by his clinic (age-specific reference ranges vary). The PCP refers him to urology. The urologist orders transrectal ultrasound and a multi-core biopsy (this becomes diagnostic, not screening, so 20 percent coinsurance applies). The biopsy returns intermediate-grade adenocarcinoma.

James undergoes multiparametric prostate MRI and a multidisciplinary tumor board review at Memorial Mercer Cancer Center. He elects active surveillance with serial PSA, MRI, and confirmatory biopsy. James continues to attend annual Medicare-covered PSA monitoring while in surveillance.

Section 1861(ddd)(3) and NCD 210.14: Lung cancer screening with low-dose CT

Lung cancer is the leading cause of cancer death in the United States, accounting for more deaths than breast, colorectal, and prostate cancers combined. The vast majority of lung cancer deaths occur in current or former smokers. Low-dose CT (LDCT) screening, demonstrated to reduce lung cancer mortality in the National Lung Screening Trial (NLST), is the only mortality-proven lung cancer screening test.

Statutory and regulatory framework

Section 1861(ddd) of the Social Security Act covers additional preventive services that USPSTF has graded A or B. Lung cancer screening with LDCT received a USPSTF Grade B recommendation and was added to Medicare coverage under NCD 210.14. The NCD has been updated as USPSTF recommendations evolved, with the most recent expansion broadening eligibility to younger and lower-pack-year beneficiaries.

Eligibility

To qualify for Medicare-covered LDCT lung cancer screening, the beneficiary must meet ALL of the following criteria (per the current NCD 210.14):

1. Age 50 to 77 (the lower bound was reduced from 55 in a recent NCD update)
2. Asymptomatic (no signs or symptoms of lung disease)
3. Tobacco smoking history of at least 20 pack-years (the pack-year threshold was lowered from 30 in a recent NCD update)
4. Current smoker, or former smoker who quit within the past 15 years
5. Order from a Medicare-enrolled provider who has documented a shared decision-making counseling visit

Verify the current NCD 210.14 parameters before scheduling, as CMS updates the eligibility criteria periodically.

A pack-year is defined as smoking the equivalent of one pack of cigarettes per day for one year. Twenty pack-years means 20 years of one-pack-per-day smoking, 10 years of two-packs-per-day, etc.

HCPCS codes

G0296 Counseling visit to discuss the need for lung cancer screening using low-dose CT scan: Required before the initial LDCT. Must document shared decision-making including discussion of benefits (mortality reduction), harms (false positives, radiation, overdiagnosis, complications of follow-up), and smoking cessation counseling/intervention.

G0297 Low dose CT scan for lung cancer screening: Annual. The radiologist must use Lung-RADS (Lung Imaging Reporting and Data System) or equivalent structured reporting.

Facility and reporting requirements

The performing facility must be a Medicare-enrolled imaging facility with ACR Designated Lung Cancer Screening Center status or equivalent accreditation. The facility must submit data to a CMS-approved registry (the American College of Radiology's Lung Cancer Screening Registry is the primary approved registry).

Cost-sharing

LDCT screening is $0 cost-sharing under ACA Section 4104 (USPSTF Grade B service). The counseling visit (G0296) is also $0.

Worked example 5: Frank, age 62, Tifton

Frank, age 62, lives in Tifton (rural south Georgia) and has Original Medicare. He smoked one pack per day from age 18 to age 48 (30 pack-years), then quit at age 48 (14 years ago, within the 15-year window). He has no lung cancer symptoms.

Frank meets all five eligibility criteria. His PCP at Tift Regional Medical Center refers him to Phoebe Putney Cancer Center in Albany (50 miles away) for shared decision-making counseling and LDCT. Phoebe is an ACR Designated Lung Cancer Screening Center.

Frank attends a 30-minute counseling visit. The pulmonologist discusses: mortality benefit (a meaningful reduction documented in the NLST), false-positive rate (a notable share of scans show a finding requiring further evaluation, most benign), radiation dose (low-dose CT delivers a small per-scan dose), overdiagnosis risk (some detected cancers may not have caused symptoms in remaining lifetime), and smoking cessation status (Frank has been quit 14 years, no current intervention needed).

Frank agrees to proceed. The counseling visit is billed G0296, $0 cost-sharing. The LDCT is performed the same day, billed G0297, $0 cost-sharing. Radiologist reports Lung-RADS 2 (benign appearance, no suspicious findings). Frank is scheduled for annual repeat LDCT.

The following year, the LDCT shows a small spiculated nodule in the right upper lobe (Lung-RADS category indicating high suspicion for malignancy). Frank is referred for diagnostic CT, PET, and biopsy (these convert to diagnostic billing, 20 percent coinsurance). The biopsy returns early-stage adenocarcinoma. Frank undergoes thoracoscopic lobectomy at Emory University Hospital (referred for cardiothoracic surgery). Five-year survival for early-stage NSCLC is dramatically higher than for advanced-stage disease. The LDCT screening allowed Frank to be diagnosed before he developed symptoms, when treatment is most effective.

The IPPE and AWV: where cancer screening conversations happen

Cancer screenings are not usually free-standing visits. They are ordered during routine primary care, particularly two specific Medicare-covered visits:

Initial Preventive Physical Examination (IPPE), Welcome to Medicare Visit

Statutory authority: Section 1861(s)(2)(W) of the Social Security Act (added by the Medicare Modernization Act of 2003).

HCPCS: G0402.

Coverage: Once within the first 12 months of Part B enrollment.

Components: review of medical and social history; review of risk factors for depression and other mood disorders; review of functional ability and safety; physical exam (height, weight, BMI, blood pressure, vision); end-of-life planning education; written screening schedule for the next 5-10 years; education and counseling on preventive services including cancer screenings; referrals as appropriate. Includes one screening EKG (G0403/G0404/G0405).

Cost-sharing: $0.

Annual Wellness Visit (AWV)

Statutory authority: Section 1861(s)(2)(FF) of the Social Security Act (added by the Affordable Care Act).

HCPCS: G0438 initial AWV (begins 12 months after IPPE or 12 months after first Part B coverage if no IPPE); G0439 subsequent AWV (every 12 months thereafter).

Components: health risk assessment (HRA); review of medical/family history; list of current providers and prescriptions; basic measurements (height/weight/BMI/blood pressure); cognitive impairment screening; depression screening; functional/safety review; personalized prevention plan including cancer screening review and orders; referrals.

Cost-sharing: $0.

Worked example 6: Doris, age 68, Columbus

Doris, age 68, lives in Columbus and is newly enrolled in Original Medicare (just turned 65 three years ago but never used her Part B beyond a few sick visits). At her PCP appointment at Piedmont Columbus Regional, her PCP suggests they catch up on preventive care via an Annual Wellness Visit.

The PCP orders G0438 (initial AWV) and bills Medicare. Doris pays $0.

During the AWV, the PCP and Doris work through her HRA. They review her family history: mother had breast cancer at age 72, father died of colon cancer at age 78. They develop her personalized prevention plan:

1. Screening colonoscopy: family history makes her high-risk (G0105). Doris has never had a colonoscopy. She is scheduled.
2. Screening mammography: Doris has had mammograms intermittently over the years but missed the last 3 years. She is scheduled (HCPCS 77067) at Piedmont Columbus Breast Center.
3. Cervical screening: Doris had a hysterectomy with removal of cervix at age 55 for fibroids (benign). USPSTF and Medicare do not recommend cervical screening after total hysterectomy for benign indication. No Pap needed.
4. Lung cancer screening: Doris is a 5-pack-year former smoker (quit 30 years ago). She does not meet the 20-pack-year/15-year-quit window threshold. Not eligible.
5. Bone density: separate from cancer screening but Doris is at risk; G0287 DEXA scheduled.
6. Influenza, pneumococcal, RSV, shingles vaccinations: covered under Part B (flu, pneumococcal, COVID) or Part D (shingles, RSV). Doris is updated.

Two months after the AWV, Doris has her screening colonoscopy at Piedmont Columbus. A small number of tubular adenomas are found and removed. She owes the polyp removal coinsurance under the CAA 2021 phase-in. Her Medicare Advantage plan covers it under her annual cap. Doris is recommended a surveillance colonoscopy within the interval her gastroenterologist sets based on adenoma findings.

Her mammogram returns BI-RADS 1 (normal). Doris is recommended annual screening.

Section 4104 of the ACA: the $0 cost-sharing framework

Before ACA Section 4104, Medicare beneficiaries paid the Part B annual deductible and 20 percent coinsurance on most preventive services, including cancer screenings. This was a substantial barrier: research consistently demonstrates that even small out-of-pocket costs reduce uptake of preventive services, especially among low-income beneficiaries.

Section 4104 of the Affordable Care Act eliminated Medicare deductible and coinsurance for preventive services that USPSTF graded A or B. Beneficiaries pay $0 for these services.

Cancer screenings covered by the $0 cost-sharing rule:

• Colorectal cancer screening (all NCD 210.3 modalities)
• Screening mammography (NCD 220.4)
• Cervical cancer screening (NCD 210.2)
• Lung cancer screening LDCT (NCD 210.14)

Prostate screening (G0103 PSA) is not USPSTF Grade A/B (currently Grade C/D) but maintains $0 cost-sharing through separate Medicare administrative and statutory practice tied to MIPPA 2008 and longstanding CMS interpretation.

What "$0 cost-sharing" does and does not cover

$0 cost-sharing applies only to the screening test itself when delivered to an asymptomatic beneficiary in conformance with NCD requirements. It does NOT cover:

1. Diagnostic services prompted by abnormal screening results: a screening colonoscopy that finds a polyp triggers polypectomy (still subject to coinsurance under the CAA 2021 phase-in, scheduled to reach $0 over a multi-year transition). A screening mammogram with BI-RADS 4 finding triggers diagnostic mammography and biopsy (20 percent coinsurance applies).

2. Specialist consultations following abnormal screening: PSA elevation prompting urology referral does not bring $0 cost-sharing for the consultation. The urology visit is a standard E/M service with 20 percent coinsurance.

3. Treatment of diagnosed cancer: $0 cost-sharing ends once cancer is diagnosed. Surgery, chemotherapy, radiation, immunotherapy, and surveillance imaging carry standard Part A or Part B cost-sharing.

4. Tests outside Medicare NCD parameters: if a test is ordered outside its covered frequency (e.g., screening mammogram before 12 months have elapsed since prior), Medicare may not cover it as screening; if covered, beneficiary may bear cost-sharing.

Anti-discrimination protection

Medicare Part C plans (Medicare Advantage) are required by CMS to cover all USPSTF Grade A/B preventive services at $0 cost-sharing, matching Original Medicare. Plans may not impose copays for covered cancer screenings. However, plans may differ in their network requirements, prior authorization, and approach to "extra benefits."

Georgia Breast and Cervical Cancer Program (BCCP)

For Georgia women who are uninsured or underinsured, the Georgia Breast and Cervical Cancer Program (BCCP) provides free or low-cost cancer screening. BCCP is administered by the Georgia Department of Public Health and funded primarily through the Centers for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program (NBCCEDP), authorized by the Breast and Cervical Cancer Mortality Prevention Act of 1990.

Eligibility

To qualify for BCCP screening in Georgia, a woman must meet all of:

1. Georgia resident
2. Household income at or below the program's Federal Poverty Level threshold (verify current dollar amounts on the BCCP page at dph.georgia.gov/BCCP)
3. Uninsured or underinsured (underinsured includes high-deductible health plans where deductible has not been met)
4. Within the program's age band for breast screening (mammography, clinical breast exam)
5. Within the program's age band for cervical screening (Pap, HPV)

Services covered

• Clinical breast examination
• Screening mammography (ages 40+)
• Pap smear
• HPV testing (ages 30+)
• Diagnostic follow-up: diagnostic mammography, ultrasound, biopsy
• Patient navigation and case management

Treatment access through Medicaid

Women diagnosed with breast or cervical cancer (or precancerous lesions) through BCCP qualify for full Medicaid coverage during the period of treatment under Georgia's Breast and Cervical Cancer Treatment program. This is a state plan option authorized by the federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.

Access points

• Phone: 1-800-220-5005
• Online: dph.georgia.gov/BCCP
• 159 Georgia counties: county health departments and partner providers across the state

Relationship to Medicare

BCCP is intended for women without Medicare or other coverage. Medicare-eligible women should generally use Medicare's $0 cost-sharing screening rather than BCCP. However, BCCP can be a bridge for women in the year before turning 65, women who declined Part B (paying late-enrollment penalty consequences), or women who have high-deductible Medicare Advantage plans where the deductible barrier is meaningful. Practitioners should help beneficiaries enroll in Part B if eligible rather than rely on BCCP for what Medicare would otherwise fully cover.

Georgia health systems and cancer screening access

Emory Winship Cancer Institute

Georgia's NCI-designated Comprehensive Cancer Center. Located at Emory University in Atlanta. Major sites: Emory University Hospital, Emory University Hospital Midtown, Emory Saint Joseph's, Emory Johns Creek, Emory Decatur. Major research themes: cancer immunology, cancer genomics, hematologic malignancies, head and neck cancer, breast cancer. Phone: 404-778-1900.

Piedmont Cancer Institute

Multispecialty oncology group operating across Piedmont Healthcare's hospital network spanning Atlanta, Fayetteville, Marietta, Newnan, Macon (Piedmont Macon), Athens, Augusta (Piedmont Augusta), Columbus (Piedmont Columbus Regional), Cartersville, Newton, Rockdale, Walton, Henry, and others. One of the largest community oncology networks in Georgia. Phone: 404-605-3489.

Augusta University Georgia Cancer Center

Major academic-medical cancer center serving the central Savannah River Area (CSRA). Affiliated with the Medical College of Georgia. Provides cancer treatment, research, and prevention. Phone: 706-721-6744.

Wellstar Cancer Network

Multi-hospital health system serving north Georgia. Wellstar STAR Cancer Center is at Kennestone Hospital in Marietta. Other major sites: Cobb, Douglas, North Fulton, Paulding, Spalding Regional, Sylvan Grove, West Georgia. Phone: 470-793-6000.

Northside Hospital Cancer Institute

Atlanta-based health system. One of the largest cancer treatment providers in Georgia by patient volume. Major sites: Atlanta, Forsyth, Cherokee, Gwinnett, Duluth. Phone: 404-851-8000.

Atrium Health Navicent Cancer Center

Macon-based cancer center serving central Georgia. Part of Advocate Health (Atrium Health and Advocate Aurora Health combined entity). Phone: 478-633-1000.

Memorial Health Mercer Cancer Center

Savannah-based cancer center serving southeast Georgia. Affiliated with Mercer University School of Medicine. Phone: 912-350-8888.

Phoebe Cancer Center

Albany-based serving southwest Georgia (including 41 surrounding rural counties). Phoebe Putney Memorial Hospital is the regional referral center. Phone: 229-312-7200.

Children's Healthcare of Atlanta (Aflac Cancer Center)

Pediatric oncology referral center; relevant for Medicare-aged survivors of childhood cancer transitioning to adult oncology.

Georgia CORE

Statewide nonprofit established 2001 as Georgia Cancer Coalition, became Georgia CORE in 2008. Coordinates clinical trials matching, cancer education, patient navigation, and cancer-care quality initiatives across Georgia health systems. Phone: 404-651-7745. Website: georgiacore.org.

Health equity in Georgia Medicare cancer screenings

Geographic disparities

Rural Georgia counties have substantially higher cancer mortality than urban counties. Contributing factors:

• Distance to screening facilities (rural beneficiaries may travel 50+ miles for screening colonoscopy or LDCT)
• Limited primary care access
• Specialist scarcity (oncology, radiology)
• Transportation barriers
• Lower screening uptake

Georgia Cancer Coalition / Georgia CORE has invested in mobile mammography units and patient navigation in rural Georgia to bridge gaps.

Racial disparities

Black Georgians have higher overall cancer mortality than White Georgians, with substantially higher mortality in:

• Prostate cancer: Black men carry roughly twice the mortality of White men
• Triple-negative breast cancer
• Cervical cancer

Causes are multifactorial: screening uptake disparities (less marked for breast and colorectal in Georgia than nationally, but still present); biological differences (more aggressive subtypes); historical and structural factors (segregated health systems persisting from pre-1965 era); social determinants (income, education, employment, geography); medical mistrust legacy (Tuskegee, Henrietta Lacks).

Emory Winship's Cancer Health Equity research portfolio and Georgia CORE's community navigation programs address these disparities.

Income disparities

A meaningful share of Georgians live below the federal poverty level. BCCP and other safety-net programs are designed to reach this population. Medicare beneficiaries with low income should also be evaluated for Medicare Savings Programs (QMB, SLMB, QI) and Extra Help (Part D Low Income Subsidy), which can reduce or eliminate the Part B premium, deductible, and coinsurance. Verify current dollar amounts on medicare.gov.

Education and language

Georgia has substantial Spanish-speaking, Korean, Vietnamese, and other immigrant communities. Cancer screening uptake is lower in non-English-primary households. Major Georgia cancer centers offer translation services and culturally tailored education materials.

Common errors and pitfalls in cancer screening

Error 1: Confusing FIT/FOBT with Cologuard frequency

The FIT/FOBT (G0328) is annual. Cologuard (G0464) is every 3 years. Beneficiaries who used Cologuard in 2024 are not eligible for another Cologuard until 2027. They are, however, eligible for annual FIT in the interim.

Error 2: Missing the colorectal screening age reduction to 45

Medicare colorectal screening is now covered starting at age 45 (was 50) following a recent Medicare Physician Fee Schedule update. Younger Medicare beneficiaries (under-65 disability-eligible, or 45-49 with Medicare) are eligible. Some practitioners may not have updated their workflow.

Error 3: Skipping shared decision-making before lung cancer screening

Medicare requires a shared decision-making counseling visit (G0296) before the first LDCT (G0297). If the LDCT is performed without G0296, the screening may be denied or the beneficiary may face unexpected charges. This is the most common LDCT screening error.

Error 4: Lung cancer screening eligibility confusion

A recent NCD 210.14 update reduced the minimum age from 55 to 50 and lowered the pack-year threshold from 30 to 20. Beneficiaries previously ineligible may now qualify. The 15-year quit window still applies (must currently smoke or have quit within past 15 years).

Error 5: Diagnostic conversion cost trap (mammography)

When a screening mammogram identifies an abnormality, follow-up imaging (diagnostic mammography, ultrasound, MRI) and biopsy are not free. 20 percent coinsurance applies. Beneficiaries without Medigap or with a high-out-of-pocket Medicare Advantage plan may face significant unexpected costs.

Error 6: Skipping the AWV

The AWV is the most efficient way to ensure all eligible cancer screenings are reviewed and ordered each year. Beneficiaries who skip the AWV (and many do) miss the opportunity for systematic screening review. A significant share of Medicare beneficiaries do not receive an AWV in a given year nationally.

Error 7: Confusing screening mammogram with diagnostic mammogram

If a beneficiary has any breast complaint (lump, pain, nipple discharge, prior abnormal imaging within past year), the appropriate test is diagnostic mammography (77065/77066), not screening (77067). Diagnostic mammography has 20 percent coinsurance. Asymptomatic beneficiaries should be sure their order is for screening if they want $0 cost-sharing.

Error 8: Prostate screening uncertainty

Many beneficiaries do not know whether they should screen for prostate cancer. USPSTF Grade C for 55-69 means individualized decision; Grade D for 70+ means recommend against. Medicare covers G0103 regardless. Beneficiaries should discuss with their PCP rather than reflexively screening or refusing.

Error 9: Cervical screening after hysterectomy

Women who have had total hysterectomy (uterus and cervix removed) for benign disease do not need Pap testing. Women who had supracervical (cervix-preserving) hysterectomy still need cervical screening. Beneficiaries should confirm with their gynecologist or PCP what type of hysterectomy they had.

Error 10: Mammography facility not FDA-certified

Medicare requires that mammography be performed at FDA-certified facilities under the Mammography Quality Standards Act 1992. Most facilities are certified, but some non-credentialed mobile units or freestanding sites are not. Beneficiaries can verify at FDA.gov.

Error 11: HPV co-testing frequency confusion

HPV co-testing (Pap + HPV) is covered every 5 years for women ages 30-65 with negative results. Standalone Pap (no HPV) is covered every 24 months avg-risk, every 12 months high-risk. The choice of test affects frequency.

Error 12: Lung cancer screening facility credentialing

LDCT must be performed at a Medicare-enrolled imaging facility with ACR Designated Lung Cancer Screening Center status or equivalent. Many small imaging centers and community hospitals are not credentialed. Beneficiaries should confirm before scheduling.

Error 13: Misunderstanding "screening" billing

"Screening" means asymptomatic; "diagnostic" means symptomatic or follow-up of abnormal screening. The clinical history at the time of the order determines billing. If a beneficiary tells the radiologist "my breast hurts" or "I felt a lump," the mammogram converts to diagnostic with cost-sharing.

Error 14: Skipping cancer screening because of advanced age or comorbidity

USPSTF generally recommends ceasing screening for colorectal cancer beyond age 85, mammography beyond age 74, cervical at 65 with adequate prior screening, prostate at 70. The reasoning: limited remaining life expectancy reduces benefit, and screening harms (false positives, biopsy complications, overtreatment of indolent cancers) may exceed benefits. However, healthy beneficiaries with greater than 10-year life expectancy may benefit from continued screening despite age guidance. Individualized decision-making with PCP is appropriate.

A few more common questions:

How often is Medicare's screening colonoscopy covered? Every 10 years for average-risk individuals (G0121), or every 4 years following a screening flexible sigmoidoscopy. Every 24 months for high-risk individuals (G0105). High-risk includes family history of colorectal cancer or polyps, personal history of polyps or inflammatory bowel disease, or hereditary syndrome.

What about Cologuard? Is it covered every year? No. Cologuard (HCPCS G0464, multitarget stool DNA test) is covered every 3 years for asymptomatic average-risk beneficiaries ages 45-85. Fecal occult blood / FIT testing (G0328) is covered annually.

A polyp was found and removed during my screening colonoscopy. What does that cost? You owe coinsurance on the polyp removal portion of the colonoscopy (not on the screening colonoscopy itself, which remains $0). CAA 2021 Section 122 phases this coinsurance out to $0 over a multi-year transition. Medigap and many Medicare Advantage plans may cover this coinsurance in the meantime.

Does Medicare cover annual screening mammograms? Yes, for women age 40 and over. HCPCS 77067 (bilateral screening mammography). No upper age limit. There is also a baseline mammogram covered once between ages 35-39.

USPSTF recommends biennial mammograms; does that mean Medicare won't cover annual? Medicare exceeds the USPSTF biennial recommendation. Medicare covers annual screening mammography (every 11 months apart) for women 40+. Use it if you and your provider agree annual is right for you.

What if my screening mammogram shows something abnormal? Follow-up diagnostic imaging (diagnostic mammography, breast ultrasound, breast MRI) and biopsy are covered by Medicare but with 20 percent coinsurance and Part B deductible. These services are not $0. Medigap supplement insurance covers the coinsurance.

How often does Medicare cover Pap smears? Every 24 months for average-risk women, every 12 months for high-risk women. High-risk includes early sexual activity, multiple lifetime partners, history of STD including HPV, abnormal prior Pap, DES daughters. HPV co-testing is covered every 5 years for women 30-65.

I had a total hysterectomy. Do I still need Pap smears? If your hysterectomy was for benign disease (fibroids, endometriosis, etc.) and the cervix was removed (total hysterectomy), no cervical screening is needed. If you had supracervical hysterectomy (cervix preserved), continue screening. If hysterectomy was for cervical cancer or high-grade dysplasia, lifetime surveillance is recommended.

Should I get a PSA test for prostate cancer screening? This is one of the more controversial screening decisions. USPSTF recommends individualized shared decision-making (Grade C) for men 55-69 and against routine screening (Grade D) for men 70+. Discuss with your primary care physician. Factors to consider: family history of prostate cancer, race, prior PSA values, life expectancy, your values regarding overdiagnosis and treatment harms. Medicare covers annual PSA (G0103) for men 50+ regardless.

Is PSA $0 to me? Yes. The PSA blood test (G0103) and the digital rectal exam (G0102) are both $0 cost-sharing. Medicare maintains this through statute.

Who is eligible for lung cancer screening? Adults age 50-77 with a tobacco smoking history of at least 20 pack-years who currently smoke or quit within the past 15 years, and are asymptomatic. A pack-year is one pack per day for one year (so 20 years of one pack per day, or 10 years of two packs per day).

What is shared decision-making for lung cancer screening? A required visit (G0296) before your first low-dose CT screening. Your provider discusses: the benefits of screening, the harms (false positives, complications of follow-up, radiation, overdiagnosis), smoking cessation support if you currently smoke, and the decision whether to proceed. This visit must be documented before screening can be performed.

What is the Annual Wellness Visit and why does it matter for cancer screening? The AWV (G0438 initial, G0439 subsequent) is a Medicare-covered annual visit ($0 cost-sharing) for personalized prevention planning. It is where your provider reviews and orders your cancer screenings each year. Skipping the AWV means cancer screenings often get missed. We strongly recommend taking advantage of your annual AWV.

What is the IPPE Welcome to Medicare visit? The IPPE (G0402) is a one-time visit within the first 12 months of Part B enrollment. It covers history, physical exam, depression screening, functional/safety review, and screening plan. After the IPPE, you transition to annual AWVs.

I am a Georgia woman without health insurance. Can I still get cancer screening? Yes. The Georgia Breast and Cervical Cancer Program (BCCP) provides free or low-cost mammography and Pap screening for uninsured/underinsured women within the program's age bands and at or below the program's income threshold. Call 1-800-220-5005 or visit dph.georgia.gov/BCCP. Women diagnosed with breast or cervical cancer through BCCP qualify for Medicaid treatment coverage.

Where is the NCI-designated cancer center in Georgia? Emory Winship Cancer Institute (Atlanta) is Georgia's NCI-designated Comprehensive Cancer Center. Call 404-778-1900. Augusta University Georgia Cancer Center is the state's other major academic cancer center.

Does Medicare cover genetic testing for cancer risk? Medicare covers some genetic testing in specific clinical contexts: BRCA1/BRCA2 testing for breast cancer (when family history meets specific criteria), Lynch syndrome testing for colorectal cancer (in select clinical scenarios), and increasingly other syndromes. Coverage is governed by Local Coverage Determinations from MACs (in Georgia, Palmetto GBA). Routine population-based genetic screening is generally not covered.

I have Medicare and Medicaid. Are cancer screenings still free? Yes. Original Medicare provides $0 cost-sharing for the screenings. If diagnostic follow-up triggers coinsurance, Medicaid as secondary payer should cover the Medicare coinsurance for dual-eligible beneficiaries (subject to state Medicaid rules; Georgia Medicaid is administered by Georgia DCH).

My provider is recommending screening at younger or older ages than Medicare covers. What do I do? Some private practice providers may recommend screening that exceeds Medicare's NCD parameters. If the test is performed outside the covered frequency or for a non-covered indication, Medicare may not cover it. You can pay out of pocket, or ask the provider whether the test meets Medicare coverage requirements before scheduling.

Where do I appeal if Medicare denies cancer screening coverage? File a Medicare appeal. The first level is "redetermination" by the MAC (Palmetto GBA in Georgia, 1-877-567-9230). Subsequent levels are reconsideration, ALJ hearing, Medicare Appeals Council, and federal district court. For help, call the Medicare Rights Center at 1-800-333-4114 or GeorgiaCares SHIP at 1-866-552-4464 for free counseling.

Cancer screening and Medicare Advantage plans

A majority of Georgia Medicare beneficiaries are enrolled in Medicare Advantage (Part C) plans, and Georgia's MA penetration sits at or above the national average. MA plans operate under different rules than Original Medicare for many services, but cancer screening is one area where federal regulations require parity. Under CMS Medicare Advantage regulations and the Medicare Managed Care Manual, MA plans must cover all USPSTF Grade A and Grade B preventive services at $0 cost-sharing, matching the Original Medicare framework established by ACA Section 4104.

What this means in practice for Georgia MA enrollees:

Screening colonoscopy, mammography, Pap, LDCT, PSA: $0 to the beneficiary at in-network facilities. No deductible, no copay, no coinsurance.

Network requirements: MA plans have networks. If you choose a facility outside the plan's network, you may face balance billing or denial of coverage. Always confirm the screening facility is in your MA network before scheduling.

Prior authorization: Some MA plans require prior authorization for certain screenings, particularly LDCT for lung cancer and screening colonoscopy. Original Medicare does not require prior authorization for these services. Confirm with your plan before scheduling.

Referral requirements: Some MA HMO plans require a PCP referral to a specialist for screening (gastroenterology for colonoscopy, radiology for mammography). Original Medicare does not require referrals. Confirm your plan's rules.

Extra benefits: Some MA plans market "enhanced cancer screening benefits" as a marketing differentiator. These often duplicate what Original Medicare already provides. Be skeptical of marketing claims; the core benefit is universal at $0.

Diagnostic follow-up: When screening identifies an abnormality requiring diagnostic follow-up (additional imaging, biopsy, consultation), MA plans apply their own copay/coinsurance structure for diagnostic services. This often differs from Original Medicare's 20 percent flat coinsurance and may include flat-dollar copays for specialist visits and per-procedure copays for imaging or biopsy. Review your plan's Summary of Benefits for the current amounts.

Annual out-of-pocket maximum: MA plans must cap your annual in-network out-of-pocket spending. CMS publishes an annual federal MOOP cap (a higher cap applies when out-of-network spending is combined). Many Georgia MA plans set lower caps than the federal ceiling. If cancer screening leads to diagnostic workup and treatment, the MA cap can protect you, but the cap resets each calendar year. Verify the current cap on medicare.gov or your plan's Summary of Benefits.

Original Medicare with Medigap

A meaningful share of Georgia Medicare beneficiaries have Original Medicare with a Medigap supplement. This combination provides the most comprehensive coverage for cancer screening and any follow-up:

• Screening: $0 (Original Medicare benefit)
• Diagnostic follow-up coinsurance: covered by Medigap (Plans G, F, N most common)
• Specialist consultations: covered (Medigap pays the 20 percent coinsurance)
• Treatment (surgery, chemotherapy, radiation): covered (Medigap pays Part A and Part B coinsurance)

The trade-off is a higher monthly premium for the Medigap policy itself (on top of the Part B premium). Premiums vary by plan, issue age, and carrier; check medicare.gov's Medigap policy search for current Georgia rates. For beneficiaries with high cancer risk or established cancer diagnoses, Medigap is often the better value.

Original Medicare without Medigap

A smaller share of Georgia Medicare beneficiaries have Original Medicare without supplemental coverage. In this configuration:

• Screening: $0
• Part B deductible: paid out of pocket for non-screening services (verify the current amount on medicare.gov)
• 20 percent coinsurance on all Part B services after deductible: no cap

This is the riskiest configuration. A single hospitalization for diagnostic workup or cancer treatment can lead to substantial out-of-pocket costs because Part B has no annual out-of-pocket maximum. Beneficiaries in this category should evaluate switching to Medigap (during Medigap open enrollment, generally the 6-month window after first enrolling in Part B at age 65+) or to a Medicare Advantage plan.

Genetic testing and hereditary cancer syndromes

A meaningful minority of cancers are due to inherited genetic mutations (Lynch syndrome, BRCA1/BRCA2, familial adenomatous polyposis (FAP), Li-Fraumeni, Cowden, etc.). Beneficiaries with strong family history of cancer should consider genetic counseling and possible testing.

Medicare coverage of genetic testing

Medicare coverage of genetic testing has expanded substantially in recent years but remains tightly tied to specific clinical scenarios under Local Coverage Determinations (LCDs) issued by the regional MAC. In Georgia, Palmetto GBA issues LCDs for Jurisdiction J.

BRCA1/BRCA2 testing: covered when family history meets specific criteria including triple-negative breast cancer in family member under 60, multiple breast/ovarian cancers in family, male breast cancer, Ashkenazi Jewish ancestry combined with breast/ovarian history, or known family BRCA mutation.

Lynch syndrome testing: covered when colorectal or endometrial tumor pathology meets Bethesda or Amsterdam criteria, or when family history meets specific patterns. Tumor MMR/MSI testing is now standard pathology for most colorectal and endometrial cancers and serves as an initial Lynch screen.

Hereditary cancer panel testing: covered in specific clinical scenarios. Routine population-based genetic screening is generally not covered.

Pre-implantation and prenatal genetic testing: not covered by Medicare (relevant to adult children of Medicare beneficiaries who may inherit mutations).

Genetic counseling

Genetic counseling is covered by Medicare under physician services (Section 1861(s)(2)(A)) when provided by a physician or qualified non-physician practitioner (NPP). Standalone genetic counseling by a non-physician certified genetic counselor (CGC) is generally not separately billable to Medicare; counseling is incorporated into physician visit codes (E/M).

Georgia genetic counseling and testing access

• Emory Winship Cancer Institute: comprehensive cancer genetics program with multiple board-certified genetic counselors
• Northside Hospital Cancer Institute: large clinical cancer genetics program
• Augusta University Cancer Center: cancer genetics counseling and testing
• Piedmont Cancer Institute: cancer genetics counseling at major sites
• Wellstar: cancer genetics counseling and testing

Insurance preauthorization is often required for hereditary cancer testing, particularly multi-gene panels. Out-of-pocket cost when not covered varies widely by panel size and lab; single-gene tests tend to be modestly priced while large multi-gene panels can run into thousands of dollars. Patient assistance programs through testing labs (Invitae, Color, GeneDx, Myriad, others) can reduce costs.

When cancer screening matters most: the prevention argument

Cancer screening is one of the highest-value preventive services in medicine. The four major adult cancers with effective screening (colorectal, breast, cervical, lung) collectively cause a large share of cancer mortality in the United States. Greater screening uptake at the population level is associated with meaningful reductions in cancer deaths that would otherwise occur.

For Medicare beneficiaries specifically, the cancer screening framework is unusually beneficiary-friendly:

• $0 cost-sharing eliminates financial barriers (the most documented driver of preventive service underuse)
• Annual primary care visits (AWV) institutionalize screening review
• Multiple modalities for colorectal screening accommodate beneficiary preferences (don't want colonoscopy? Use Cologuard or FIT)
• No upper age limits in statute (though clinical guidance shifts to individualized at advanced age)
• Network breadth in Georgia: a large multi-hospital Piedmont network, Wellstar, multiple major academic and community cancer centers across Atlanta, Augusta, Macon, Savannah, Columbus, Albany, and rural Georgia
• Safety-net wrap (BCCP for women not yet Medicare-eligible or with coverage gaps)

The remaining barrier is principally awareness and primary care engagement. Beneficiaries who attend an annual AWV are far more likely to be up-to-date on screening than those who do not. If you have Medicare, schedule your AWV. If you have not had your Medicare cancer screenings, ask your PCP at your next visit. The cost is $0 and the benefit can be lifesaving.

For the Georgia families navigating cancer concerns: take advantage of Georgia's robust cancer infrastructure. From Emory Winship in Atlanta to Phoebe Cancer Center in Albany, screening and treatment access is broadly available. The Georgia Breast and Cervical Cancer Program backstops coverage gaps for women. Georgia CORE coordinates statewide. Medicare backs the financial framework. The pieces are in place; the work is taking advantage of them.